Tirzepatide tends to cause fewer gastrointestinal side effects (nausea and vomiting) compared to Semaglutide, despite showing more significant weight loss over time
Providers who push faster titration may get patients to therapeutic doses sooner, but they also lose more patients to intolerable side effects
Semaglutide reduces major adverse cardiovascular events, heart failure composite, cardiovascular death, and all-cause death in patients with atherosclerotic cardiovascular disease and overweight or obesity and heart failure
227,228 Obstructive sleep apnea (frequent bouts of airway narrowing or collapse, breathing interruption [apnea], and waking during sleep) affects an estimated 10% of the population
8, 2025 Have we replaced food noise with mom guilt